NASDAQ:BCAB BioAtla Q4 2025 Earnings Report $1.52 -0.07 (-4.40%) As of 09/24/2026 01:05 PM Eastern ProfileEarnings HistoryForecast BioAtla EPS ResultsActual EPS-$8.00Consensus EPS -$18.00Beat/MissBeat by +$10.00One Year Ago EPSN/ABioAtla Revenue ResultsActual Revenue$2.00 millionExpected Revenue$0.70 millionBeat/MissBeat by +$1.30 millionYoY Revenue GrowthN/ABioAtla Announcement DetailsQuarterQ4 2025Date3/31/2026TimeBefore Market OpensConference Call DateTuesday, March 31, 2026Conference Call Time7:00AM ETUpcoming EarningsBioAtla's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) BioAtla Earnings HeadlinesBioAtla Announces $40 Million Oncology SPV Investment DealMay 29, 2026 | theglobeandmail.comBioAtla Announces Share ConsolidationMarch 31, 2026 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsMarch 31, 2026 | globenewswire.comBioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder ValueMarch 2, 2026 | quiverquant.comQBioAtla Announces Formal Process to Evaluate Strategic Options to Monetize AssetsMarch 2, 2026 | globenewswire.comSee More BioAtla Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioAtla? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAtla and other key companies, straight to your email. Email Address About BioAtlaBioAtla (NASDAQ:BCAB) is a biotechnology company focused on developing antibody-based therapeutics for cancer and other serious diseases. The company’s research has centered on its Conditionally Active Biologics (CAB) technology, which is designed to create antibodies that are preferentially activated in the tumor microenvironment while remaining less active in healthy tissues. BioAtla’s oncology pipeline has included programs directed at targets such as ROR2 and CTLA-4. Its lead candidates have included ozuriftamab (BA3021), an antibody targeting ROR2, and evalstotug (BA3071), an investigational CTLA-4-directed antibody. These programs have been evaluated in clinical studies involving patients with advanced solid tumors, either as standalone treatments or in combination with other cancer therapies. Founded in 2007 and headquartered in San Diego, California, BioAtla conducted its discovery and clinical-development activities primarily in the United States, with clinical research involving international study sites. The company has undergone strategic changes as it evaluated its development programs and corporate alternatives, and publicly available information about its current operations and leadership may be limited.View BioAtla ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
